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Abstract
Purpose—To determine the cumulative incidence of optic disc hemorrhage (ODH) before and 
after development of primary open angle glaucoma (POAG); determine the prognostic significance 
of ODH for the development of POAG; identify predictive factors for ODH.
Design—Prospective cohort study.
Methods—ODHs were evaluated in 3,236 eyes of 1618 Ocular Hypertension Treatment Study 
(OHTS) participants annually using stereoscopic optic disc photographs. The incidence of ODH 
before and after the development of POAG, the risk of ODH for POAG, and risk factors for ODH 
were determined using a multivariate proportional hazards regression models.
Results—After a median follow-up of 13 years, one or more ODHs were detected in 179 eyes of 
169 participants. The incidence of ODH was 0.5% per year during an average of 13 years before 
the development of POAG and 1.2% per year during an average of 6 years after the development 
of POAG. The cumulative incidence of POAG in eyes with ODH was 25.6% compared to 12.9% 
in eyes without ODH. The occurrence of an ODH increased the risk of developing POAG 2.6-fold 
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in the multivariate analysis (95% confidence interval, 1.7– 4.0; P<0.0001). Randomization to the 
observation group, older age, thinner central corneal thickness, larger vertical cup to disc ratio, 
higher intraocular pressure, and self-reported black race were identified as risk factors for ODH.
Conclusion—ODH is an independent predictive factor for the development of POAG in patients 
with ocular hypertension (OHT) and the predictive factors for ODH are very similar to those for 
POAG in OHT patients.
Introduction
Optic disc hemorrhages (ODH) can occur in a variety of ocular disease states, such as 
posterior vitreous detachment, optic neuropathy, retinal vascular disease, and glaucoma. 
They have been shown to be predictive of future glaucomatous damage in patients with 
primary open angle glaucoma (POAG)1–5 and normal tension glaucoma.5–10 More recently, 
ODHs have been shown to precede retinal nerve fiber layer thinning detected by Optical 
Coherence Tomography (OCT) in patients with glaucoma.11–15 There is also evidence that 
structural and functional glaucomatous changes may precede the occurrence of ODH.16–18 
Whether ODHs are a precursor to, or marker of, glaucomatous damage, the literature 
supports that they are a predictive factor for progression in patients with glaucoma.19 
However, fewer studies have addressed the issue of whether ODHs are a risk factor for the 
development of POAG in patients with ocular hypertension (OHT). In an interim report of 
the Ocular Hypertension Treatment Study after a total median follow-up of 8 years,20 we 
reported that identification of an ODH increased the risk of developing POAG 3.7-fold in a 
multivariate analysis that included baseline factors predictive of the development of POAG. 
Subsequently, the European Glaucoma Prevention Study confirmed that ODH was an 
independent risk factor for POAG with a hazard ratio of 1.97 in a similar multivariate 
analysis.21 Since there can be a delay between the appearance of an ODH and changes in the 
visual field or optic disc, additional participants who developed POAG after an ODH may 
have been identified later in the follow-up of the OHTS The purpose of the current report is 
to update results at 13 years (median) follow-up, which is an additional 5 years more than in 
our previous report.20 In this paper we report: 1. the cumulative incidence of ODH before 
and after development of POAG; 2. determine the prognostic significance of ODH for the 
development of POAG; 3. to identify factors predictive for ODH, including the development 
of POAG.
Subjects and Methods
Methods for the detection and definition of what constituted a glaucomatous ODH in 
OHTS1 have been described in detail previously20 and did not change between OHTS1 and 
OHTS2. An ODH was considered to be related to glaucoma if there was a flame- or splinter-
shaped hemorrhage that was in the nerve fiber layer of the neuroretinal rim or retina and 
perpendicularly oriented to the edge of the optic disc either on or immediately adjacent to 
the optic disc. Hemorrhages associated with optic disc swelling or those accompanied by 
retinal hemorrhages consistent with retinal vascular occlusion or diabetic retinopathy were 
not considered glaucomatous hemorrhages. The presence of an ODH at the baseline visit 
was an exclusion criterion for potential OHTS participants, but was not considered a POAG 
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endpoint.22 Annually, stereoscopic optic disc photographs were evaluated by two masked 
(non-MD) readers at the OHTS Optic Disc Reading Center (ODRC), and readers were asked 
to determine whether an ODH was present or not. If the two readers disagreed, the 
photographs were referred to a senior (MD) reader for adjudication. As part of the current 
report, all photographs that were determined to contain an ODH by the ODRC were re-
reviewed by two of the study authors (DLB and SJG) to confirm the presence of an ODH 
and to determine whether the hemorrhage met the criteria for a glaucomatous hemorrhage as 
defined in the OHTS1 analysis.20 All evaluations were done with the readers and 
investigators masked to randomization group and diagnostic status. The current report used 
all of the data collected during the median 13 year follow-up of the OHTS. The analysis of 
whether ODH is a predictive factor for the onset of POAG used ODH prior to the 
development of POAG through OHTS 1 and 2. The analysis of predictive factors for ODH 
included time to development of ODH including subjects who developed ODH at the same 
visit or after the development of POAG.
The analysis data set included the complete OHTS database, which includes data from 
baseline randomization through March 2009. To determine whether ODH was predictive of 
the development of POAG, a univariate Cox proportional hazards model was performed with 
detection of ODH during follow-up as a time-dependent factor. Only ODHs prior to the time 
of the 1st suspicious date of the development of POAG were included in Cox model. The 
robust sandwich variance estimate option was used to account for the correlation between 
the 2 eyes of participants. To determine if ODH was an independent factor predictive of the 
development of POAG, ODH was added as a time-dependent factor to the published OHTS 
Cox prediction model that includes age, vertical cup-to-disc ratio, pattern standard deviation 
index on visual field testing, intraocular pressure (IOP), and central corneal thickness 
(CCT). 23
To identify factors, including the development of POAG, that were predictive of ODH 
through 13 years of follow-up, univariate and multivariate Cox proportional hazards models 
were performed. All data from randomization through the development of ODH or the last 
optic disc photograph of the participant were included. Predictors in univariate Cox models 
with p<0.05 were tested in the multivariate Cox proportional hazard model and retained in 
the multivariate model if statistically significant at P=0.05. Covariates in Cox models 
included POAG status as a time-dependent variable. Robust sandwich variance estimate 
option was used to account for the correlation between the 2 eyes of participants. The 
cumulative incidence of ODH was assessed with Kaplan-Meier analyses to account for 
variable follow-up time.
Results
The OHTS data files from February 1994 through March 2009 were used in this report. The 
median follow-up was 13 years for 1,636 participants. POAG developed in 362 eyes of 279 
participants, including 213 eyes (59%) by optic disc criteria alone, 129 eyes (36%) by visual 
field criteria alone, and 20 eyes (5%) by both. The cumulative incidence of eyes with at least 
one ODH before POAG by follow-up years 1 through 14 was 0.37% (n =12), 0.92% (n =29), 
1.6% (n = 49), 2.2% (n = 66), 2.5% (n =75), 2.9% (n = 85), 3.6% (n= 104), 4.0% (n = 115), 
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4.6% (n=129), 5.2% (n=143), 5.7% (n=154), 6.4% (n=168), and 7.0% (n=179), respectively, 
or 0.5% per year.
Overall, and by randomization group, the cumulative incidence of eyes with at least one 
ODH at 13 years of follow up was 8.5%, including 7.4 % in the medication group and 9.8% 
in the observation group. The Figure shows the cumulative incidence of ODHs in the 
medication and observation groups over the median 13 years of follow-up. ODHs occurred 
less frequently in the medication group compared to the observation group, the hazard ratio 
was statistically significant (HR= 0.70, 95% CI 0.52 – 0.95, P = 0.02, Cox proportional 
hazards model). Table 1 displays a frequency distribution of ODHs detected in 179 eyes of 
the 169 participants prior to POAG and in non-POAG eyes. 3093 eyes had no disc 
hemorrhages and, of those, 322 developed POAG, 300 had no subsequent ODHs but 42 did. 
Of the 179 eyes with ODH, 139 (78%) did not develop POAG during a median follow-up of 
49 months after the disc hemorrhage and 40 eyes (21.6%) subsequently developed a POAG 
endpoint after 36 months (median) – 20 eyes (50%) by optic disc criteria after 37 months 
(median), 18 eyes (45%) by visual field criteria after 20.4 months (median), and 2 eyes (5%) 
by both after 90.7 months (median).
Of the 362 eyes in which POAG developed, 32 eyes of 30 participants had documented 
ODHs after the development of POAG after a median follow-up of 53.7 months. Table 1 also 
displays the frequency distribution of ODHs in 32 eyes of 30 participants after a diagnosis of 
POAG. Twenty-two (69%) of these 32 eyes had no documented ODHs before the POAG 
endpoint and 10 (31%) had at least one pre-POAG ODH. Among the 22 eyes that had no 
documented ODHs prior to POAG, the cumulative incidence of the post-POAG ODHs from 
1 to 6 years was 2.8% (n= 8), 4.9% (n=13), 6.5% (n=16), 7.8% (n=18), 9.2% (n=20), and 
10.0 % (n=21), respectively, or approximately 1.2% per year. There was one eye with the 
initial ODH 11 years after the first POAG endpoint. The maximum number of POAG ODHs 
after reaching a POAG endpoint was 6 in a single eye. No difference was found in the 
incidence of post- POAG ODHs between participants who had reached POAG by disc 
criteria versus field criteria (P= 0.17).
To assess whether ODH increased the risk of POAG, ODH was included as a time-
dependent covariate in a Cox proportional hazards model of time to POAG. The risk of 
developing POAG after occurrence of an ODH was 3.98 times higher than without an ODH 
(hazard ratio, 3.98; 95% confidence interval, 2.7 –5.9; P<0.0001). After adjusting for 
baseline factors in the published OHTS Cox prediction model of POAG,21,23 and 
randomization assignment, the independent contribution of ODH to risk was less (hazard 
ratio, 2.6; 95% confidence interval, 1.7– 4.0; P<0.0001).
In univariate Cox proportional hazards models, baseline variables significantly predictive 
(p<0.05) of ODH were age, CCT, vertical cup to disc ratio, PSD, IOP, history of heart 
disease, gender, randomization group and self-reported race (Table 2). POAG status as a 
time dependent variable in the univariate model did not statistically significantly increase the 
risk of ODH (p=0.09). The final multivariate model for ODH showed that increased age, 
thinner CCT, larger vertical CD ratio, higher IOP, self-reported black race and randomization 
to observation were predictive of ODH (Table 3). Factors that were not statistically 
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significant in the multivariate model included history of heart disease (p=0.30), female 
gender (p=0.64) and PSD (p=0.08).
Discussion
Bjerrum first reported the association between ODH and glaucoma in 1889.24 However, it 
was not until 1970 that Drance and Begg further described the relationship between ODH in 
open-angle glaucoma.25 Numerous studies have subsequently explored ODH as a risk factor 
for the development and progression of glaucoma.1–15 More recently, several studies have 
demonstrated abnormalities in the optic disc and retinal nerve fiber layer and visual field that 
precede the development of an ODH in glaucoma patients. 16–18
ODH typically appear as a flame- or splinter-shaped hemorrhage extending radially from the 
optic nerve head to the adjacent retina, and this shape is a result of the orientation of the 
axons in the retinal nerve fiber layer. ODH may be subtle and mistaken for a blood vessel on 
cursory examination. Even experienced clinicians may miss an ODH,20 and they are not 
detected with devices that image the optic nerve and RNFL such as optical coherence 
tomography. Therefore, optic disc photographs are considered the most sensitive detection 
method for ODH.
Development of an ODH may be related to biomechanical forces influencing the lamina 
cribrosa and surrounding tissues including the IOP, cerebrospinal fluid pressure, arterial 
pressure, and venous pressure.26 Cigarette smoking and a history of heart disease were 
associated with an increased risk of ODH in OHTS, providing supporting evidence that 
vascular factors are important in the pathogenesis of ODH. It is unclear whether ODH play a 
causative role in glaucoma progression or whether they are simply a marker for the disease. 
Blood is known to be neurotoxic as a result of extravasated inflammatory cells, hemoglobin, 
and thrombin.27,28
Baseline factors associated with ODH in the multivariate Cox proportional hazards model 
were older age, larger vertical cup to disc ratio, thinner central corneal thickness, IOP and 
self-reported race. Participants randomized to the medication group had lower incidence of 
ODH than participants randomized to the observation group. Many of the baseline factors 
that were associated with an increased risk of ODH were also associated with an increased 
risk of developing POAG.23 However, ODH remained an independent predictor of glaucoma 
in the multivariate analysis.
ODH occur more commonly in eyes with glaucoma or OHT than in normal eyes, and their 
frequency is higher in normal-tension glaucoma than high-tension glaucoma. The cross 
sectional prevalence of ONH has been reported to range from 0 to 0.4% in normal eyes, 
0.4% to 10% in eyes with OHT, 4.2% to 17.6% in eyes with high-tension glaucoma, and 
20.5% to 33.3% in eyes with normal-tension glaucoma in population- and clinic-based 
studies.29–31 The incidence of ODH has ranged from 0.04 to 0.34 times per year in eyes with 
high-tension glaucoma and 0.11 to 0.46 times per year in eyes with normal-tension 
glaucoma in clinic-based studies. 31–33 The incidence of ODH was approximately 0.5% per 
year in the setting of this multicenter randomized clinical trial of participants with OHT 
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prior to development of POAG and with follow-up spanning more than a decade. This is 
likely an underestimate for two reasons. First, because participants with ODH at baseline 
were excluded from the OHTS cohort due to uncertainty at the time as to whether ODH was 
a sign of early POAG or a risk factor, the participants enrolled in OHTS only included those 
who did not have ODH at baseline and were probably less likely to have ODH during 
follow-up. Second, ODHs are transient, usually resolving within 2 months.29 Since 
photographs were only taken annually and ODHs may appear and resolve undetected 
between photographs, the incidence is likely higher than reported here.
Numerous studies have described an increased risk of visual field progression1–10,34–36 and 
neuroretinal rim/RNFL thinning 11–15,37,38 in glaucoma patients with ODH. However, the 
relationship between ODH and progression to glaucoma in patients with OHT is less well 
described. Drance and colleagues1 studied 29 patients with OHT and ODHs to 29 ocular 
hypertensive patients without ODHs and found 10 patients who progressed to glaucoma in 
the ODH group compared to only one in the group without ODHs. Airaksinen and coauthors 
looked retrospectively at 25 patients with OHT and found that 8 developed glaucomatous 
optic nerve or visual field changes over a follow-up of 1 to 2 years; however, no control 
group was studied.39 In a retrospective study of 17 OHT patients, Siegner and Netland5 
found that those with ODHs were more likely to develop glaucomatous optic nerve or visual 
field changes compared to OHT patients without ODHs. The European Glaucoma 
Prevention Study was a prospective randomized trial similar to OHTS, comparing treatment 
to observation in patients with OHT. That study found that intercurrent ODH increased the 
risk of developing POAG by 1.97,21 similar to the magnitude of increased risk of 2.8 in this 
report.
Although the presence of an ODH was associated with an increased risk of developing 
POAG in the OHTS, the majority of eyes (78%) with an ODH did not progress to glaucoma 
over a median follow-up of 49 months after ODH. ODH may occur with other ocular 
conditions, including posterior vitreous detachment, optic nerve drusen, retinal vascular 
occlusion, ischemic optic neuropathy, and papilledema.26,40 ODH may also develop in 
association with a systemic condition, such as diabetes mellitus, hypertension, leukemia, or 
systemic lupus erythematosus. We attempted to exclude participants with these conditions in 
the present analysis.
The long-term analysis of the OHTS data shows a strong relationship between 
randomization to treatment group and ODH. Participants in the treatment group had a 30% 
lower hazard ration for an ODH. This was not found in the OHTS 1 analysis20 but there was 
a trend in this direction (risk ratio 0.75; 95% CI 0.53 – 1.09, P = 0.13). It is likely that the 
increased number of ODHs and the longer follow-up in the longitudinal analysis resulted in 
this trend becoming statistically significant. Several studies have examined the relationship 
between IOP lowering treatment and the frequency of ODH. Hendrickx et al observed that 
reduction of IOP significantly decreased the number of ODH in patients with high-tension 
glaucoma, but not in patients with normal-tension glaucoma.32 Miyake et al found a 
significant reduction in the frequency of ODH after trabeculectomy with mitomycin C 
compared to preoperative rates in both high-tension and normal-tension glaucoma patients,33 
suggesting that those patients with profound IOP lowering have a reduced risk of ODH. 
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Medeiros et al found that, in eyes with ODH, IOP-lowering therapy slowed the velocity of 
VF progression compared to pre-treatment.41 In contrast, the Early Manifest Glaucoma Trial 
(EMGT) demonstrated that the presence or frequency of ODH was not related to IOP 
lowering therapy.42
Although the OHTS was the largest and longest study to look at the predictive factors 
associated with the development of POAG in people with OHT, there are several limitations 
to the current analysis. First, while surveillance for ODH was performed every 6 months by 
study investigators and annually using stereoscopic disc photos, we only used data from 
annual photographs because we could not verify that ODHs identified by investigators fit the 
strict definition of “glaucomatous” optic disc hemorrhages. It is possible that ODHs were 
observed in between annual photographs and had time to resolve since they are known to be 
transient. This would result in observation bias resulting in an underestimate of the incidence 
of optic disc hemorrhages. Second, ODH was the only intercurrent, or non-baseline 
predictive factor, considered in this analysis. It is possible that other intercurrent predictive 
factors such as level of IOP, fluctuations in IOP, compliance with medical therapy, and other 
factors increase the risk of developing POAG and might affect the predictive risk of ODH on 
POAG if they were included in a multivariate risk analysis model. It is hoped that future 
analysis of the OHTS dataset will incorporate these potential predictive factors into a 
comprehensive risk calculator. OHTS 3, which is a new study to re-examine the original 
OHTS cohort seven and eight years after completion of OHTS 2, may add refinement to the 
current estimates of hazard ratios as well as help develop a comprehensive risk calculator 
that considers all measured intercurrent predictive factors.
In summary, the present study demonstrates a low incidence of ODH in participants with 
OHT alone (0.5%/year) but a doubling of the incidence of ODH after POAG has developed 
(1.2%/year). Intercurrent ODH increased the risk of developing POAG in participants almost 
three fold. Since the occurrence of an ODH is a strong predictor of the subsequent 
development of POAG in patients with OHT, we recommend careful examination of the 
optic nerve at all follow-up visits to detect ODH. More frequent monitoring should be 
undertaken if an ODH is detected in a patient with OHT and institution or escalation of 
medical therapy may be advisable in some cases. Older age, larger vertical cup:disc ratio, 
thinner central corneal thickness, higher IOP and self-reported African-American race were 
factors predictive of ODH in multivariate models.
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Figure. 
Cumulative incidence of participants who developed an optic disc hemorrhage in the Ocular 
Hypertension Treatment Study. The hazard ratio for developing a disc hemorrhage in the 
medication group was 0.70 with a 95% CI 0.52 – 0.95, P=0.02.
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